Pacira Pharmaceuticals (PCRX) Stock Forecast & Price Target

Pacira BioSciences is being acquired by Viatris for $36.50 per share in an all-cash transaction worth about $1.65 billion, a ~45% premium and roughly 9.3x LTM adjusted EBITDA, which underscores a full valuation supported by a clean tender structure and no financing contingency. The offer is also backed by more than $50 million of annual run-rate cost synergies through end-2028, which helps bridge the gap to value while making the deal immediately accretive and leaving Pacira holders with limited upside beyond the bid absent a competing offer. Fundamentally, Pacira’s appeal comes from its high-margin non-opioid pain franchise—EXPAREL with about $587 million of LTM revenue, ZILRETTA with about $121 million, and a ~340-person specialty sales force—plus longer-term optionality from PCRX-201 and international expansion rights.

Pacira BioSciences is viewed negatively because the investment case is now dominated by a deal that may fail rather than by durable fundamentals, with a non-waivable >50% minimum tender condition, HSR clearance, and a potential $62MM termination fee all adding execution risk. The company’s core asset, EXPAREL, remains exposed to active Paragraph IV/ANDA challenges, possible generic competition, and reimbursement pressure if the NOPAIN Act expires at the end of 2027, while its growth initiatives like nerve blocks and PCRX-201 still face meaningful uncertainty. Even with ZILRETTA and iovera, the business remains concentrated and vulnerable to product, regulatory, legal, and commercialization risk, making a failed or terminated transaction likely to drive shares back toward pre-announcement levels around $25.